Podcast

Louise Liu Joins Antiverse's The Future of Drug Discovery Podcast

Hill Research |
Louise Liu Joins Antiverse's The Future of Drug Discovery Podcast

Hill Research CEO Dr. Louise Liu joins Murat Tunaboylu, Co-Founder and CEO of Antiverse, on The Future of Drug Discovery podcast.

The Setup

The statistical programming behind an FDA submission is one of the slower steps in clinical development. Eight programmers, six months, and roughly eight million dollars is what it takes to produce the data package for a single Phase 3 trial.

Louise and her team are doing this work with one person in 90 minutes using generative AI.

What the Episode Covers

  • How Hill Research’s technology actually works under the hood
  • What the FDA thinks about the use of AI in clinical trial submissions
  • The questions pharma executives have about pinpointing accountability when AI is added into the clinical pipeline

Listen

  • Spotify
  • Available on every other major podcast platform

Learn More